5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Phase A, members will receive different doses and schedules of oral ABBV-744 pill to identify Harmless dosing routine. Further participants will probably be enrolled for the recognized monotherapy dosign program. In Section B, contributors will get oral ruxolitinib and ABBV-744 will likely be offered as "add-on" therapy. In Section C, contributo